Astellas Takes Option on Audax's Preclinical IL-12 Cancer Drug
- Astellas has taken an exclusive option to license a preclinical immuno-oncology asset, an IL-12 therapy, from Australian biotech Audax Biosciences.
- Per Endpoints, the $285 million figure covers the upfront fee plus a payment that falls due if Astellas exercises the option; the upfront share is not broken out in the available excerpt.
💡 Points Based on public reports
IL-12 is a potent but historically toxic cytokine, so Astellas is paying for the right to wait for Audax to show it can be dosed safely. An option keeps its commitment small until that data exists, which fits the cautious, optionality-first posture many big players now take with preclinical immuno-oncology.
Astellas buys option on preclinical IL-12 cancer drug from Audax Biosciences ↗